Johnson & Johnson Announces 1-Yr Results From Phase 3 FUZION Study Showing TREMFYA Maintained Or Improved Fistula Remission Through 48 Weeks In Adults With Crohn's Disease

Johnson & Johnson (NYSE: JNJ) announced one-year results from the Phase 3 FUZION study, revealing that TREMFYA (guselkumab) maintained or improved fistula remission in adults with Crohn's disease through 48 weeks. The remission rate increased from 28% at Week 24 to 35% at Week 48 in the 100 mg dose group. These results support the efficacy of TREMFYA in treating challenging manifestations of Crohn's disease and were presented at the 2026 United European Gastroenterology Week.